HT-61, also known as HY-50A, is a pyrroloquinolone antibiotic potentially for the treatment of staphylococcal infections. HT61 was effective at reducing biofilm viability and was associated with increased expression of cell wall stress and division proteins, confirming its potential as a treatment for S. aureus biofilm infections. HT61 enhances the effect of tobramycin against Pseudomonas aeruginosa in vitro and in vivo.

VU0364572 TFA is an orally active and selective allosteric agonist of the M1 muscarinic receptor.

SHP099 is a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor with IC50 =0.07 μM and p-ERK modulation in cells IC50 = 0.250 μM. SHP099 exhibits dose-dependent pathway inhibition and antitumor activity in xenograft models. SHP2 is a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also purportedly plays an important role in the programmed cell death pathway (PD-1/PD-L1). Because it is an oncoprotein associated with multiple cancer-related diseases, as well as a potential immunomodulator, controlling SHP2 activity is of significant therapeutic interest.

VU0364572 free base is an orally active and selective allosteric agonist of the M1 muscarinic receptor.

Tubulin inhibitor 32 is a potent and orally active tubulin inhibitor.

NDM-1 inhibitor-3 (Compound 89) is a New Delhi Metallo-β-lactamase-1 (NDM-1) inhibitor

ARTD3/PARP3-IN-1 is an unselective inhibitor of diphtheria toxin-like ADP-ribosyltransferase 3 (ARTD3)/PARP3.

CpCDPK1/TgCDPK1-IN-3 (Compound 20) is a CpCDPK1 and TgCDPK1 inhibitor

S1R agonist 2 (Compound 8b) is a selective S1R agonist.

(-)-GSK598809 is an isomer of GSK598809. GSK598809 is a selective D(3)R antagonist recently progressed in Phase I trials. GSK-598809 may decrease the rewarding effects of contextual cues associated with drug intake preclinically, which may reduce drug craving in humans.

Prulifloxacin, also known as NM-441, is an inhibitor of bacterial DNA gyrase used to treat urinary tract infections. Prulifloxacin is an oral fluoroquinolone with a broad in vitro activity spectrum against Gram positive and negative bacteria and among fluoroquinolones has the lowest power of inducing resistance. In vitro and in vivo studies have shown its clinical efficacy and pathogen eradication.

L-Tyrosine is an aromatic, polar, non-essential amino acid that contains a highly reactive α-amino, α-carboxyl, and phenolic hydroxyl group. L-tyrosine modulates biofilm formation of Bacillus cereus ATCC 14579. L-Tyrosine Limits Mycobacterial Survival in Tuberculous Granuloma.

SARS-CoV-2-IN-39 (compound 21) is a SARS-CoV-2 inhibitor with an EC50 of 1 μM.

Mtb-IN-2 (compound 10c) is an antimicrobial agent against Mycobacterium tuberculosis (Mtb).

Xanthine oxidoreductase-IN-4 is an orally active xanthine oxidoreductase (XOR) inhibitor.

DC-Y13-27, a derivative of DC-Y13, is a YTHDF2 inhibitor (KD: 37.9 μM).

sEH inhibitor-14 (compound 33) is a benzoxazolone-5-urea analogue.

STAT3-IN-15 is a potent and orally active STAT3 inhibitor.

FC-116 is a Tubulin inhibitor that effectively inhibits tumor growth in mice.

URAT1 inhibitor 7 (compound 10f) is a potent URAT1 inhibitor.

Vestitone reductase catalyzes a stereospecific NADPH-dependent reduction of (3R)-vestitone in the bio sysnthesis of antimicrobial isoflavonoid phytoalexin medicarpin.

HDAC-IN-58 is a HDAC inhibitor.

Antitumor agent-109 (compound 6) is an inhibitor of hyaluronic acid (HY-B0633A) targeting to CD44.

HA5 inhibits Streptococcus mutans biofilm.

BCAT-IN-4 (Compound 1) is a BCAT inhibitor.

Orziloben is a medium chain fatty acid (MCFA) analogue.

BLK degrader 1 (compound 9) is a selective degrader of B-lymphoid tyrosine kinase (BLK).

Xanthine oxidoreductase-IN-5 is an orally active xanthine oxidoreductase (XOR) inhibitor

Pimicotinib, also known as ABSK021, is a tyrosine kinase inhibitor and antineoplastic. It is a small molecule CSF-1R inhibitor that is orally available. Pimicotinib has antitumor activity and a solid white to off-white appearance. Its formula is C22H24N6O3 and its CAS number is 2253123-16-7.

Rezatapopt, also known as PC14586, is p53 Y220C reactivator that binds selectively to p53 Y220C mutant protein and restores the p53 wildtype conformation and transcriptional activity, resulting in potent preclinical antitumor activity. PC14586 was structurally designed to bind tightly to a crevice within the mutant protein (KD~2.5 nM). PC14586 was shown to stabilize the Y220C mutant in the wild type conformation, resulting in reactivation of p53 transcriptional activity and subsequent expression of its target proteins (e.g. p21, MDM2, Bax, PUMA). The reactivation of p53 function is highly selective to Y220C mutant cells and results in arrest of the cell cycle in vitro (IC50 ~0.230-1.8 μM). In nude mice bearing Y220C mutant NUGC3 gastric cancer xenograft tumors, oral administration of PC14586 results in a dose responsive anti-tumor effect. In human xenografts, PC14586 was shown to convert Y220C mutant to the wildtype conformation, resulting in activation of p53 transcription.